ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e [f] g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1283

Factors Affecting Mortality of Systemic Lupus Erythematosus Patients in Spain in the 21st Century: Data from the RELESSER Registry
Abstract Number: 0771

Factors Associated to Clinical and Radiographic Disease Progression in Patients with Early RA and First-degree Relatives: A 1-year Follow-up
Abstract Number: 1720

Factors Associated with an Increased Risk of Imminent Rheumatoid Arthritis in ACPA+ Individuals
Abstract Number: 0263

Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus
Abstract Number: 1293

Factors Associated with Early Hospital Readmission in Systemic Lupus Erythematosus: Data from National Readmission Database
Abstract Number: 1183

Factors Associated with Incident Heart Failure Subtypes in Patients with Rheumatoid Arthritis Using Electronic Health Record Data
Abstract Number: 0628

Factors Associated with Knee Osteoarthritis in an Outpatient HIV-1 Clinic over a 26 Year Interval
Abstract Number: 0388

Factors Prognostic of Greater Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the Placebo Group of the SENSCIS Trial
Abstract Number: 0804

Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands
Abstract Number: 0552

Fast Food Habits and Serum Urate Change in Young Adults: 15-Year Prospective Cohort Analysis
Abstract Number: 1946

Fast-Track Giant Cell Arteritis Clinic Experience in the United States
Abstract Number: 1314

Fatigue in Psoriatic Arthritis (PsA): Prevalence in Patients from the US and Europe, and Impact on Quality of Life and Work Productivity
Abstract Number: 0514

Feasibility of 18F-fluorodeoxyglucose Positron Emission Tomography to Monitor the Effect of Tocilizumab on Vascular Inflammation in Giant Cell Arteritis: A Prospective Observational Cohort Study
Abstract Number: 1564

Feasibility of Ultra-low-dose, Short-duration, Total-body Evaluation of Inflammatory Arthritis Using uEXPLORER 18F-FDG PET/CT
Abstract Number: 0588

Feast or Famine? An Institutional Assessment of Hydroxychloroquine Screening Practices
Abstract Number: 1247

Features of Childhood Sjogren’s Syndrome: A Literature Review Based Cohort
Abstract Number: 0696

Femoral Cartilage Ultrasound Echo-Intensity Associates with Arthroscopic Cartilage Damage in People Following Anterior Cruciate Ligament Reconstruction
Abstract Number: 1771

Fertility and Pregnancy Outcomes in Women with Spondyloarthritis: A Systematic Review and Meta-analysis
Abstract Number: 0206

Fifty-Two Week Outcomes of Biologic-Naïve RA Patients Treated with Subcutaneous Abatacept in Japanese Multicenter Investigational Study (ORIGAMI Study)
Abstract Number: 0142

Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs: Results from the FINCH 2 Study
Abstract Number: 0141

Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results from FINCH-1 Study
Abstract Number: 0143

Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis Who Are Methotrexate-naïve: Results from the FINCH-3 Study
Abstract Number: 1528

Filgotinib Inhibits Monocyte Differentiation and Pro Inflammatoly Cytokine Production in Osteoblasts
Abstract Number: 1216

Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, and Health Related Quality of Life, and Reduced Fatigue over Time in Patients with Rheumatoid Arthritis Who Are Methotrexate-Naïve: Results from a Phase 3 Study
Abstract Number: 1218

Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, Health-related Quality of Life, and Fatigue in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
Abstract Number: 1215

Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
Abstract Number: 0136

Filgotinib Significantly Improved Patient-reported Health-related Quality of Life for Patients with Active Rheumatoid Arthritis: A Post Hoc Analysis of SF-36 and HAQ-DI from Phase 3 Studies
Abstract Number: 1561

Findings Compatible with Axial Spondyloarthritis in Radiologist Reports
Abstract Number: 0490

Fine Specificity Anti-Citrullinated Protein Antibodies as Biomarkers for Prediction of Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 1827

Flare Reduction and Oral Corticosteroid Taper in Patients with Active SLE Treated with Anifrolumab in 2 Phase 3 Trials
Abstract Number: 0326

Flares Among Patients with Psoriatic Arthritis (PsA) – Frequency and Impact on Patient Outcomes: Real-world Survey in the US and Europe
Abstract Number: 1751

Forecasting Healthcare Utilization in Rheumatoid Arthritis: A Machine Learning Predictive Model of Emergency Department Visits and Prednisone Initiation in a Single Tertiary Academic Center
Abstract Number: 1504

Four Distinct Symptom-Based Clusters Identified from the Sjӧgren’s Foundation Survey
Abstract Number: 0891

Four-Year Efficacy and Safety of Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis: A Pooled Analysis from VOYAGE 1 and VOYAGE 2
Abstract Number: 0119

Fracture Liaison Service at an Academic Center with an Open Health System: 30-month Outcomes
Abstract Number: 0422

Frailty and Health-Related Quality of Life in Patients with Polymyalgia Rheumatica
Abstract Number: 1535

Frequency and Anatomic Distribution of Magnetic Resonance Imaging Lesions in the Sacro-iliac Joints of Healthy Subjects and Patients with Spondyloarthritis
Abstract Number: 1618

Frequency and Cost of Repeat HLA-B27 Testing Within the National Capital Consortium over a Calendar Year
Abstract Number: 1292

Frequency and Predictors of Influenza Vaccine Hesitancy in Systemic Autoimmune Rheumatic Diseases
Abstract Number: 1164

Frequency of Genetic Diagnosis in an Autoinflammatory Disease Natural History Protocol Cohort of Patients
Abstract Number: 1559

Fully Automatic Assessment of Nail Fold Capillaroscopy Software – Early Results
Abstract Number: 1455

Functional Characterization of PLCG2 Mutations Found in Subjects with Autoinflammation and PLCG2-Associated Antibody Deficiency and Immune Dysregulation (APLAID) Reveals Both Hypermorphic and Hypomorphic Mutants
Abstract Number: 0067

Functionally Mature CD1c+ Dendritic Cells Contribute to Synovial Inflammation in Rheumatoid Arthritis via STAT3

Jump to: View All • a b c d e [f] g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].